The data suggest this burden among patients who have myasthenia gravis (MG) is prevalent across insurance types. Exacerbations of myasthenia gravis (MG) are associated with both clinical and economic ...
A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter. Eculizumab (Soliris; Alexion) is an effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results